<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645866</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000582618</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC0132</secondary_id>
    <secondary_id>595-02</secondary_id>
    <secondary_id>378-ONC-0030-241</secondary_id>
    <nct_id>NCT00645866</nct_id>
  </id_info>
  <brief_title>Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer</brief_title>
  <official_title>A Neo-Adjuvant Study of Sequential Epirubicin and Docetaxel in Combination With Capecitabine in Patients With Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as epirubicin, docetaxel, and capecitabine, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of giving epirubicin together with&#xD;
      docetaxel and capecitabine and to see how well it works in treating women with stage IIIA or&#xD;
      stage IIIB breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Describe the pathologic response rate in chemotherapy-naive women with locally advanced&#xD;
           breast cancer (stage IIIA or IIIB) after 6 courses of sequential neoadjuvant therapy&#xD;
           with epirubicin hydrochloride and a combination of docetaxel with capecitabine .&#xD;
&#xD;
        -  Describe the adverse events of sequential epirubicin hydrochloride and a combination of&#xD;
           docetaxel with capecitabine in this patient population.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Identify by transcriptional profiling the differential expression of candidate gene&#xD;
           products that confer chemosensitivity to epirubicin hydrochloride, docetaxel, and&#xD;
           capecitabine.&#xD;
&#xD;
        -  Correlate the differential expression of known genetic polymorphisms of intracellular&#xD;
           regulators involved in the metabolism of epirubicin hydrochloride, docetaxel, and&#xD;
           capecitabine with adverse events and tumor response.&#xD;
&#xD;
        -  Assess individual patient variation in clinical (toxicity and/or activity), in&#xD;
           pharmacologic (pharmacokinetic/pharmacodynamic parameters), and/or biologic (correlative&#xD;
           laboratory study results) responses to epirubicin hydrochloride, docetaxel, and&#xD;
           capecitabine due to genetic differences in proteins involved in drug response&#xD;
           (transport, metabolism and/or mechanism of action).&#xD;
&#xD;
      OUTLINE: Patients receive epirubicin hydrochloride IV on day 1. Treatment repeats every 2&#xD;
      weeks for 3 courses. Beginning 2 weeks after last dose of epirubicin hydrochloride, patients&#xD;
      receive docetaxel IV over 1 hour on day 1 and oral capecitabine twice daily on days 1-14.&#xD;
      Treatment with docetaxel and capecitabine repeats every 3 weeks for 3 courses. Patients then&#xD;
      undergo surgery.&#xD;
&#xD;
      Blood samples are collected at baseline for pharmacogenetic studies. Tumor tissue samples are&#xD;
      collected at baseline and periodically during treatment for correlative laboratory studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months until disease&#xD;
      progression and then every 6 months for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity patterns</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacogenomic studies</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic surgical procedure</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
               -  Stage IIIA or IIIB disease (T3 N1 M0, T4 N1 M0, any T N2/N3 M0)&#xD;
&#xD;
          -  Bidimensionally measurable or evaluable disease&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Platelet count ≥ 100,000 cells/μL&#xD;
&#xD;
          -  Total bilirubin normal&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  ANC ≥ 1,000 cells/μL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min and serum creatinine normal&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No chronic debilitating disease&#xD;
&#xD;
          -  No lack of physical integrity of the upper gastrointestinal tract&#xD;
&#xD;
          -  Able to swallow tablets&#xD;
&#xD;
          -  No malabsorption syndrome&#xD;
&#xD;
          -  No clinically significant cardiac disease not well controlled with medication (e.g.,&#xD;
             congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias&#xD;
             [New York Heart Association class III-IV heart disease] or myocardial infarction&#xD;
             within the last 12 months)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except for adequately treated basal cell&#xD;
             or squamous cell skin cancer or adequately treated other noninvasive carcinomas&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 1&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  No prior chemotherapy regimens including adjuvant therapy&#xD;
&#xD;
          -  No organ allograft&#xD;
&#xD;
          -  No concurrent sorivudine or bruvidine&#xD;
&#xD;
          -  No other concurrent cytostatic, cytotoxic, immunomodulating agents, or radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian R. Molina, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James N. Ingle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wilma Lingle, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>March 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Julian R. Molina, M.D., Ph.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

